Hydroxyprogesterone caproate is under clinical development by Lipocine and currently in Phase II for Premature Labor (Tocolysis). According to GlobalData, Phase II drugs for Premature Labor (Tocolysis) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Hydroxyprogesterone caproate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hydroxyprogesterone caproate overview
Hydroxyprogesterone caproate (LPCN-1107) is under development for the prevention of preterm birth. LPCN-1107 is human progestogen and acts by targeting progesterone receptor. The drug candidate is administered through oral route. It is based on Lip'ral technology.
Lipocine operates as a pharmaceutical company that develops and commercializes treatments for men’s and women’s health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021, and for women’s health include LPCN 1107. It’s LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with a positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of preterm birth. It develops patented technology based on lipidic compositions that form an optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip’ral is a technology based on lipidic compositions that form optimal dispersed phases in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, US
For a complete picture of Hydroxyprogesterone caproate’s drug-specific PTSR and LoA scores, buy the report here.